Clear cell hidradenoma

Shahmoradi, Zabihollah; Mokhtari, Fatemeh

doi:10.4103/2277-9175.109742

Cited by 9 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4]. • A few reports are available in literature regarding presence of this tumour on occipital region [3]. It typically presents as a painless nodule, consistent with our case.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Nodular Hidradenoma of the Scalp: A Rare Case Report

Kumar,

Ahmed,

Pawanarkar

et al. 2024

Sur Res J

View full text Add to dashboard Cite

Nodular hidradenoma is a rare benign tumour originating from eccrine or apocrine sweat glands. While documented cases exist in the medical literature, nodular hidradenoma of the scalp is relatively uncommon. We present a rare case of nodular hidradenoma located on the scalp to contribute to the limited knowledge regarding its clinical presentation, diagnosis, management and outcomes in this specific anatomical site. We present a case of a 45-year-old female with a nodular hidradenoma of the scalp. The patient complained of a slow growing swelling, itchy, slightly tender scalp lump over 9 years period. Clinical examination revealed a well-defined, firm nodule measuring 3.5 x 3 cms in diameter with 2 cms wide stalk. The patient underwent complete surgical excision, resulting in a favourable outcome for regular follow up to one year

show abstract

“…[4]. • A few reports are available in literature regarding presence of this tumour on occipital region [3]. It typically presents as a painless nodule, consistent with our case.…”

Section: Discussionsupporting

confidence: 86%

“…• Clear cell hidradenoma or nodulocystic hidradenoma or acrospiroma are histologically distinct relatively rare tumours of sweat gland duct origin, found mainly in adults with a female preponderance [3]. • It affects all ages, most commonly females in fourth to eighth decades of life.…”

Section: Discussionmentioning

confidence: 99%

Nodular Hidradenoma of the Scalp: A Rare Case Report

Kumar,

Ahmed,

Pawanarkar

et al. 2024

Sur Res J

View full text Add to dashboard Cite

show abstract

“…CCH may be asymptomatic or may present with pain, or bleeding, and rarely can show malignant transformation [10]. Ulcerated lesions may resemble squamous cell carcinoma, basal cell carcinoma metastatic disease or other adnexal tumors [11][12][13]. Dermoscopy shows a nodule of amorphous, white-pink areas, red lacuna-like areas, eccentric ulceration, as well as hairpin, dotted, and linear irregular vessels [14].…”

Section: Discussionmentioning

confidence: 99%

Clear Cell Hidradenoma of the Inguinal Area: A Rare Tumor in an Uncommon Location

Zinoune¹,

Douhi²,

Baybay³

et al. 2019

Madridge J Case Rep Stud

View full text Add to dashboard Cite

Nodular hidradenomas are benign sweat gland-derived tumors that can produce clinical and dermatoscopic misdiagnoses. Histologically, these tumors can be classified into eccrine and apocrine subtypes. Clear cell hidradenoma is a rare benign eccrine tumor, it's representing 1% of all skin tumors, found mainly in adult females. The lesions are usually solitary and are most likely to be found on the scalp, face or anterior trunk. We report a case of clear cell hidradenoma developing in the inguinal area in a 68-year old man, which occurred during the course of nine months. The clinical and histologic findings of the tumor are documented. The lesion was totally removed by excision and revealed no evidence of recurrence. Through this case, we would like to highlight the unusual location of this hidradenoma.

show abstract

“…Additionally, this study showed that 89% of cancer cells in colorectal tumors that metastasize to lymph nodes express EPCAM, and 10% express it less. 124…”

Section: Epithelial Cellular Adhesion Molecule (Epcam)mentioning

confidence: 99%

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance

Kusumaningrum,

Makaba,

Ali

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

The majority of cancer cases are colorectal cancer, which is also the second largest cause of cancer‐related deaths worldwide. Metastasis is the leading cause of death for patients with colorectal cancer. Metastatic colorectal cancer incidence are on the rise due to a tiny percentage of tumors developing resistant to medicines despite advances in treatment tactics. Cutting‐edge targeted medications are now the go‐to option for customized and all‐encompassing CRC care. Specifically, multitarget kinase inhibitors, antivascular endothelial growth factors, and epidermal growth factor receptors are widely used in clinical practice for CRC‐targeted treatments. Rare targets in metastatic colorectal cancer are becoming more well‐known due to developments in precision diagnostics and the extensive use of second‐generation sequencing technology. These targets include the KRAS mutation, the BRAF V600E mutation, the HER2 overexpression/amplification, and the MSI‐H/dMMR. Incorporating certain medications into clinical trials has significantly increased patient survival rates, opening new avenues and bringing fresh viewpoints for treating metastatic colorectal cancer. These focused therapies change how cancer is treated, giving patients new hope and better results. These markers can significantly transform and individualize therapy regimens. They could open the door to precisely customized and more effective medicines, improving patient outcomes and quality of life. The fast‐growing body of knowledge regarding the molecular biology of colorectal cancer and the latest developments in gene sequencing and molecular diagnostics are directly responsible for this advancement.

show abstract

Clear cell hidradenoma

Cited by 9 publications

References 9 publications

Nodular Hidradenoma of the Scalp: A Rare Case Report

Nodular Hidradenoma of the Scalp: A Rare Case Report

Clear Cell Hidradenoma of the Inguinal Area: A Rare Tumor in an Uncommon Location

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance

Contact Info

Product

Resources

About